Driven by strong pharma sales, the company's revenues rose to $687 million from $629 million in Q4 2016, besting the consensus analyst estimate of $669 million.
Developed by researchers at the University of Michigan, the software could help drive uptake of ion mobility mass spec within the top-down proteomics field.
The company entered an agreement with JP Morgan Chase that provides a five-year unsecured $300 million term loan and a $1.5 billion revolving facility.
The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.
Waters experienced some sluggishness in the US market in the quarter, and the firm noted that its pharma business, in particular, had seen a shift toward Europe.
The agreement brings together Biognosys' Spectronaut Pulsar DIA software and Waters' SONAR data-independent acquisition mass spectrometry method.
The company posted Q2 revenues of $558.3 million, up from $536.6 million in Q2 2016 and beating the average Wall Street estimate of $553.1 million.
Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.
As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.
The approval covers Waters' Acquity UPLC and Acquity UPLC I-Class systems, as well as its Xevo TQD, Xevo TQ-S micro, and Xevo TQ-S mass spectrometers.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.